KAPA net incomeQ2 2026-$1.39M
KAPA net income was -$1.39M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.42M a year earlier. For the full fiscal 2025 it was -$5.45M, compared with -$2.60M in fiscal 2024.
Kairos Pharma Ltd. (KAPA) financials
For the twelve months ended Jun 30, 2026, Kairos Pharma Ltd. reported -$5.80M of net income.
- Net income, TTM
- -$5.80M
- EPS, diluted, TTM
- -$0.28
- Cash
- $2.63M
- Market cap
- $1.6M
FY2023FY2025
KAPA revenue and earnings growth
KAPA EPSQ2 2026-$0.06
KAPA diluted EPS was -$0.06 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.08 a year earlier. For the full fiscal 2025 it was -$0.30.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Research and development | $2.13M | $414.0K | $82.0K |
| Selling, general and admin | $3.44M | $1.93M | $1.63M |
| Operating income | -$5.57M | -$2.34M | -$1.71M |
| Interest expense | - | $35.0K | $42.0K |
| Net income | -$5.45M | -$2.60M | -$1.81M |
| EPS, basic | -$0.30 | -$0.23 | -$0.17 |
| EPS, diluted | -$0.30 | -$0.23 | -$0.17 |
| Diluted shares | 18.4M | 11.4M | 10.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $4.49M | $1.27M | $93.0K |
| Current assets | $5.39M | $4.17M | $101.0K |
| Total assets | $6.54M | $5.77M | $965.0K |
| Current liabilities | $199.0K | $992.0K | $2.40M |
| Long-term debt | - | - | $638.0K |
| Total debt | - | - | $638.0K |
| Total liabilities | - | $992.0K | $3.04M |
| Shareholders' equity | $6.34M | $4.78M | -$2.08M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$3.44M | -$3.96M | $81.0K |
| Financing cash flow | $6.66M | $5.13M | -$425.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $619.0K | $684.0K | $538.0K | $608.0K | $496.0K | $493.0K | $172.0K | $14.0K | $63.0K | $165.0K | $7.0K | $33.0K |
| Selling, general and admin | $798.0K | $1.01M | $877.0K | $827.0K | $960.0K | $773.0K | $1.27M | $369.0K | $159.0K | $122.0K | $1.08M | $254.0K |
| Operating income | -$1.42M | -$1.69M | -$1.42M | -$1.44M | -$1.46M | -$1.27M | -$1.45M | -$383.0K | -$222.0K | -$287.0K | -$1.09M | -$287.0K |
| Interest expense | - | - | - | - | - | - | $0 | $12.0K | $12.0K | $16.0K | $3.0K | $15.0K |
| Net income | -$1.39M | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -$980.0K | -$1.05M | -$253.0K | -$323.0K | -$1.12M | -$312.0K |
| EPS, basic | -$0.06 | -$0.08 | -$0.07 | -$0.07 | -$0.08 | -$0.08 | -$0.08 | -$0.10 | -$0.02 | -$0.03 | - | -$0.03 |
| EPS, diluted | -$0.06 | -$0.08 | -$0.07 | -$0.07 | -$0.08 | -$0.08 | -$0.08 | -$0.10 | -$0.02 | -$0.03 | - | -$0.03 |
| Diluted shares | 21.4M | 21.0M | - | 20.2M | 17.2M | 15.9M | - | 10.9M | 10.6M | 10.6M | - | 10.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.63M | $3.67M | $4.49M | $5.58M | $3.03M | $3.62M | $1.27M | $3.22M | $21.0K | $40.0K | $93.0K | $99.0K |
| Current assets | $3.17M | $4.44M | $5.39M | $6.66M | $4.84M | $6.05M | $4.17M | $4.74M | - | - | $101.0K | - |
| Total assets | $4.46M | $5.74M | $6.54M | $8.07M | $6.67M | $7.94M | $5.77M | $5.00M | - | - | $965.0K | - |
| Current liabilities | $265.0K | $431.0K | $199.0K | $402.0K | $676.0K | $805.0K | $992.0K | $1.67M | - | - | $2.40M | - |
| Long-term debt | - | - | - | - | - | - | - | - | - | - | $638.0K | - |
| Total debt | - | - | - | - | - | - | - | - | - | - | $638.0K | - |
| Total liabilities | - | - | - | - | - | - | $992.0K | $1.67M | - | - | $3.04M | - |
| Shareholders' equity | $4.19M | $5.31M | $6.34M | $7.66M | $6.00M | $7.13M | $4.78M | $3.33M | -$2.65M | -$2.40M | -$2.08M | -$1.87M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.01M | -$1.04M | -$1.08M | -$838.0K | -$805.0K | -$714.0K | -$1.80M | -$2.02M | -$168.0K | $36.0K | $66.0K | - |
| Financing cash flow | -$37.0K | $220.0K | $0 | $3.38M | $223.0K | $3.06M | -$142.0K | $5.22M | $149.0K | -$89.0K | -$72.0K | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 11.98 | 10.31 | 27.07 | 16.56 | 7.16 | 7.52 | 4.20 | 2.84 | - | - | 0.04 | - |
Source: XBRL data Kairos Pharma Ltd. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
KAPA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| KAPA | - | - | -$5.80M | - | $1.6M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
KAPA FAQ
5 questionsIs KAPA profitable?
No. Kairos Pharma Ltd. reported a net loss of $5.80M for the twelve months ended Jun 30, 2026.How much cash and debt does KAPA have?
Kairos Pharma Ltd. reported $2.63M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is KAPA earnings per share?
Diluted earnings per share were -$0.28 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did KAPA last report financial results?
The latest statements here come from Kairos Pharma Ltd.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this KAPA financial data come from?
Quantisnow builds these statements from the structured XBRL data Kairos Pharma Ltd. files with the SEC. It is provided for information only and is not investment advice.